Now available ZIIHERA® 

ZIIHERA® (zanidatamab-hrii) is a bispecific HER2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.

Please see full prescribing information here.